UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

The New England journal of medicine, 2020-11, Vol.383 (21), p.2018-2029

2020

Volltextzugriff (PDF)

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

The lancet oncology, 2019-12, Vol.20 (12), p.1691-1701

2019

Volltextzugriff (PDF)

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2019-06, Vol.37 (16), p.1370-1379

2019

Volltextzugriff (PDF)

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

Journal of clinical oncology, 2017-04, Vol.35 (10), p.1112-1118

2017

Volltextzugriff (PDF)

Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response

Clinical cancer research, 2020-05, Vol.26 (9), p.2176-2187

2020

Volltextzugriff (PDF)

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine

Clinical cancer research, 2019-03, Vol.25 (6), p.1727-1736

2019

Volltextzugriff (PDF)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Journal for immunotherapy of cancer, 2018-10, Vol.6 (1), p.109-109, Article 109

2018

Volltextzugriff (PDF)

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2022-12, Vol.174, p.146-156

2022

Volltextzugriff (PDF)

Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts

Cancer science, 2020-02, Vol.111 (2), p.536-547

2020

Volltextzugriff (PDF)

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2020-03, Vol.8 (1), p.e000530

2020

Volltextzugriff (PDF)

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

Journal for immunotherapy of cancer, 2022-01, Vol.10 (1), p.e003697

2022

Volltextzugriff (PDF)

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors

Current oncology (Toronto), 2021-12, Vol.28 (6), p.5466-5479

2021

Volltextzugriff (PDF)

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

The lancet oncology, 2017-12, Vol.18 (12), p.1590-1599

2017

Volltextzugriff (PDF)

Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor

Investigational new drugs, 2019-04, Vol.37 (2), p.271-281

2019

Volltextzugriff (PDF)

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (11), p.e007353

2023

Volltextzugriff (PDF)

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study

Journal for immunotherapy of cancer, 2023-06, Vol.11 (6), p.e006747

2023

Volltextzugriff (PDF)

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

The lancet oncology, 2018-12, Vol.19 (12), p.1654-1667

2018

Volltextzugriff (PDF)

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

Journal of clinical oncology, 2018-11, Vol.36 (32), p.3223-3230

2018

Volltextzugriff (PDF)

Targeting PI3 kinase in cancer

Pharmacology & therapeutics (Oxford), 2015-02, Vol.146, p.53-60

2015

Volltextzugriff (PDF)

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Nature medicine, 2021-05, Vol.27 (5), p.802-805

2021

Volltextzugriff (PDF)

Clinical Management of Adverse Events Associated with Lorlatinib

The oncologist (Dayton, Ohio), 2019-08, Vol.24 (8), p.1103-1110

2019

Volltextzugriff (PDF)

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

JTO clinical and research reports, 2022-01, Vol.3 (1), p.100262-100262, Article 100262

2022

Volltextzugriff (PDF)

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK -Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study

Journal of clinical oncology, 2022-11, Vol.40 (31), p.3593-3602

2022

Volltextzugriff (PDF)

Al0.68Sc0.32N Lamb wave resonators with electromechanical coupling coefficients near 10.28

Applied physics letters, 2021-04, Vol.118 (17)

2021

Volltextzugriff (PDF)

1 – 25 von 612

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(585)
Mit Volltextzugriff
(533)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

Targeting PI3 kinase in cancer

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Clinical Management of Adverse Events Associated with Lorlatinib

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK -Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study

Al0.68Sc0.32N Lamb wave resonators with electromechanical coupling coefficients near 10.28

Suchergebnisse filtern